Drug intelligence / Profile preview

LMX (lidocaine)

Development stage
Approved
Lead developer
Ferndale Laboratories
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Topical
01

Overview

LMX is a brand of topical anesthetic cream containing lidocaine encapsulated in a liposomal delivery system. The liposomal matrix is designed to enhance the penetration of lidocaine through the stratum corneum into the deeper layers of the dermis, providing a relatively rapid onset of localized anesthesia compared to traditional topical formulations. Lidocaine, the active ingredient, is a small molecule local anesthetic that works by binding to and blocking voltage-gated sodium channels on the internal surface of neuronal membranes. This action inhibits the influx of sodium ions required for the initiation and conduction of nerve impulses, effectively blocking pain signals from reaching the central nervous system. LMX is commonly used to reduce procedural pain associated with minor dermatological interventions, venipuncture, laser treatments, and skin biopsies. It is available in 4% (LMX-4) and 5% (LMX-5) concentrations and is widely utilized in both pediatric and adult clinical settings.

Brand names
LMXLMX-4LMX4LMX 4LMX-5LMX5LMX 5
Other names
liposomal lidocainelidocaine liposomal
02

Targets

SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on LMX (lidocaine).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMX (lidocaine).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call